Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Resmetirom (THR-beta, Non-incretin Benchmark)

MARKETED

thyroid hormone receptor-beta agonist (NON-incretin context benchmark)

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

Resmetirom (THR-beta, Non-incretin Benchmark) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Resmetirom (THR-beta, Non-incretin Benchmark) MARKETED
hepatic-mash Decrease
Moderate evidence

CONTEXT BENCHMARK (NON-incretin). Resmetirom (Rezdiffra, Madrigal) is the FIRST FDA-approved MASH drug, approved on the MAESTRO-NASH histological co-primaries....

Harrison SA, Bedossa P et al. MAESTRO-NASH. N Engl J Med 2024;390:497-509. Source
Full findingCONTEXT BENCHMARK (NON-incretin). Resmetirom (Rezdiffra, Madrigal) is the FIRST FDA-approved MASH drug, approved on the MAESTRO-NASH histological co-primaries. Included as the regulatory/efficacy benchmark against which incretin MASH efficacy is read, NOT as a class finding. Like ESSENCE it gained accelerated approval on histological SURROGATES; hard-outcome confirmation has not yet read out. Cross-trial comparison with ESSENCE is informal only (different populations, no head-to-head).
PopulationMAESTRO-NASH (NCT03900429), phase 3, 3 arms (80/100 mg/placebo), n=966 primary-analysis. Biopsy NASH fibrosis F1B/F2/F3; F4/CIRRHOSIS EXCLUDED. 52 wk.
Fundingindustry - Madrigal Pharmaceuticals
Scope limitssurrogate/exploratory endpoint
Comparatorsplacebo; resmetirom 80 mg; resmetirom 100 mg